{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["54"],"submitter":["Chin YH"],"pubmed_abstract":["<h4>Background</h4>There is a growing number of trials examining the effectiveness of pharmacotherapies for obesity, however, little is known about placebo and nocebo effect in these trials. Hence, we sought to examine the effect of placebo in obesity trials, to better understand the potential factors affecting clinical endpoints in them.<h4>Methods</h4>Medline, Embase, and Cochrane CENTRAL were searched for articles examining weight-loss RCTs examining patients with overweight or obesity in placebo-controlled arms from inception till 25 June 2022. This paper was registered online with PROSPERO (CRD42022302482). A single arm meta-analysis of proportions was used to estimate the primary outcomes, ≥5%, ≥10%, and ≥15% total weight loss - and the adverse effects that patients experienced durin"],"journal":["EClinicalMedicine"],"pagination":["101685"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9526167"],"repository":["biostudies-literature"],"pubmed_title":["The placebo response rate and nocebo events in obesity pharmacological trials. A systematic review and meta-analysis."],"pmcid":["PMC9526167"],"pubmed_authors":["Muthiah MD","Tang A","Noureddin M","Chan KE","Lim WH","Wang JW","Tan DJH","Sanyal A","Cummings DE","Chew NW","Siddiqui MS","Shabbir A","Kong G","Huang DQ","Figtree G","Wong VW","Chin YH","Ng CH","Khoo CM","Chan MY","Syn N","Young DY"],"additional_accession":[]},"is_claimable":false,"name":"The placebo response rate and nocebo events in obesity pharmacological trials. A systematic review and meta-analysis.","description":"<h4>Background</h4>There is a growing number of trials examining the effectiveness of pharmacotherapies for obesity, however, little is known about placebo and nocebo effect in these trials. Hence, we sought to examine the effect of placebo in obesity trials, to better understand the potential factors affecting clinical endpoints in them.<h4>Methods</h4>Medline, Embase, and Cochrane CENTRAL were searched for articles examining weight-loss RCTs examining patients with overweight or obesity in placebo-controlled arms from inception till 25 June 2022. This paper was registered online with PROSPERO (CRD42022302482). A single arm meta-analysis of proportions was used to estimate the primary outcomes, ≥5%, ≥10%, and ≥15% total weight loss - and the adverse effects that patients experienced durin","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-19T11:33:30.993Z","creation":"2025-04-19T11:33:30.993Z"},"accession":"S-EPMC9526167","cross_references":{"pubmed":["36193169"],"doi":["10.1016/j.eclinm.2022.101685"]}}